Core Viewpoint - The company, Brainstorm Aurora-B (06681), has seen its stock price increase by over 4%, currently trading at 4.83 HKD with a transaction volume of 48.71 million HKD, following the announcement of a strategic partnership with Macau Kiang Wu Hospital to enhance digital health services for cognitive disorders [1] Group 1 - The company’s subsidiary, Brainstorm Aurora Medical Technology (Macau) Limited, has signed a cooperation agreement with Macau Kiang Wu Hospital to provide digital AI technology services for brain health [1] - The partnership aims to establish a comprehensive health management model covering "hospital-community-home" for cognitive disorder screening, assessment, training, and management in the Macau region [1] - The board believes this collaboration sets a benchmark for the group and opens up the Greater Bay Area market, marking the first flagship project for the group’s digital therapy in the Hong Kong-Macau region [1] Group 2 - The collaboration enriches the company's ecosystem alliance with authoritative medical institutions, complementing a recent national-level project partnership with the National Rehabilitation Aids Research Center under the Ministry of Civil Affairs [1] - This initiative aims to promote the standardization and large-scale application of cognitive digital therapies [1]

Core Viewpoint - The company Brainstorm Aurora-B (06681) has signed a strategic cooperation agreement with the Macau Kiang Wu Hospital to establish a comprehensive brain health service model in the Macau region, focusing on digital screening, assessment, training, and health management for cognitive disorders [1] Group 1 - The company's stock rose by 4.32%, reaching HKD 4.83, with a trading volume of HKD 48.71 million [1] - The partnership with the influential private hospital in Macau is seen as a benchmark for the company, paving the way for future expansion in the Greater Bay Area [1] - This collaboration enhances the company's ecosystem alliance with authoritative medical institutions, complementing its recent national-level project cooperation with the National Rehabilitation Aids Research Center [1]

Group 1 - Healthblooming Limited increased its stake in Brainstorm Cell Therapeutics Inc. (06681) by acquiring 9.8 million shares at a price of HKD 4.0279 per share, totaling approximately HKD 39.4734 million [1] - Following the acquisition, Healthblooming Limited's total shareholding in Brainstorm Cell Therapeutics Inc. reached 68.904 million shares, representing a 5.44% ownership stake [1] - The transaction involved other related parties, specifically Zhao Yujie [1]

Group 1 - Healthblooming Limited increased its stake in Brainstorm Cell Therapeutics Inc. (06681) by acquiring 9.8 million shares at a price of HKD 4.0279 per share, totaling approximately HKD 39.4734 million [1] - Following this transaction, Healthblooming Limited's total shareholding in Brainstorm Cell Therapeutics Inc. is now 68.904 million shares, representing a 5.44% ownership stake [1] - The transaction involves other related parties, specifically Zhao Yujie [1]

Group 1 - The stock of Brainstorm Cell Therapeutics Inc. (06681.HK) rose nearly 5% in the morning session on February 9, 2023, and was up 3.96% at the time of reporting, trading at HKD 4.73 [2] - The trading volume reached HKD 55.6368 million [2]

消息面上，脑动极光-B发布公告，于2026年2月5日，本公司接获由ZTan Limited(一间由本公司执行董 事、董事会主席兼首席策略官谭铮先生全资拥有的英属处女群岛公司)发出的自愿承诺函，内容关于 ZTan Limited已自愿承诺就其于本公司股份的直接权益，接受仅以本公司为受益人的禁售承诺(禁售承 诺)。 脑动极光-B(06681)午前涨近5%，截至发稿，涨3.96%，报4.73港元，成交额5563.68万港元。 截至本公告日期ZTan Limited受禁售承诺规限的股份数目约为2.75亿股股份，受禁售承诺规限的最后日 期为2027年2月5日。董事会相信，禁售承诺彰显ZTan Limited对本公司长期发展坚定信心及体现其对本 集团长期价值与发展前景的坚定支持。 ...

消息面上，脑动极光-B发布公告，于2026年2月5日，本公司接获由ZTan Limited(一间由本公司执行董 事、董事会主席兼首席策略官谭铮先生全资拥有的英属处女群岛公司)发出的自愿承诺函，内容关于 ZTan Limited 已自愿承诺就其于本公司股份的直接权益，接受仅以本公司为受益人的禁售承诺(禁售承 诺)。 智通财经APP获悉，脑动极光-B(06681)午前涨近5%，截至发稿，涨3.96%，报4.73港元，成交额5563.68 万港元。 截至本公告日期ZTan Limited受禁售承诺规限的股份数目约为2.75亿股股份，受禁售承诺规限的最后日 期为2027年2月5日。董事会相信，禁售承诺彰显ZTan Limited对本公司长期发展坚定信心及体现其对本 集团长期价值与发展前景的坚定支持。 ...

Core Viewpoint - The company has signed a strategic cooperation agreement with Macau's Kiang Wu Hospital to establish a comprehensive brain health service model, focusing on cognitive impairment screening, assessment, training, and health management in the Macau region [1][2]. Group 1: Cooperation Details - The collaboration will involve the establishment of a "Brain Health Center" within Kiang Wu Hospital, providing a one-stop service from early screening to digital cognitive training and follow-up management [1]. - The services will cater to all age groups, including individuals aged 60 and above at risk of cognitive impairment and children aged 3 to 18 with neurodevelopmental disorders, offering both in-hospital and home-based digital therapy [1]. - Data security and compliance will be ensured by localizing data storage and processing in accordance with Macau's laws, preventing data from being transmitted outside the region [1]. Group 2: Strategic Significance - This partnership is expected to set a benchmark and expand the company's market presence in the Greater Bay Area, serving as a model for future projects in other cities [2]. - The collaboration aims to accumulate high-quality real-world data for further scientific research on cognitive function diseases, enhancing diagnostic services and product development [2]. - The initiative addresses the urgent health needs in Macau, potentially reducing the incidence of severe dementia and providing sustainable service revenue for the company [2]. Group 3: Academic and Research Collaboration - The partnership will enhance the company's ecosystem by integrating resources from mainland and Macau experts, promoting the construction of a brain health medical center and related clinical research [2][3]. - This collaboration aligns with the company's recent national-level project with the Ministry of Civil Affairs, fostering the standardization and large-scale application of cognitive digital therapies [3].

Core Viewpoint - The company has signed a strategic cooperation agreement with Macau Kiang Wu Hospital to establish a comprehensive brain health service model in the Macau region, focusing on digital screening, assessment, training, and health management for cognitive disorders [1] Group 1 - The agreement is between the company's wholly-owned subsidiary, Brain Dynamics Aurora Medical Technology (Macau) Co., Ltd., and Macau Kiang Wu Hospital [1] - The collaboration aims to create a long-term strategic partnership to enhance brain health services [1] - The new service model will cover a full chain of brain health services from "hospital - community - home" [1]

Core Viewpoint - The company has established a strategic partnership with Macau's Kiang Wu Hospital to develop a comprehensive brain health service model, focusing on cognitive impairment screening, assessment, training, and management in the Macau region [1][2]. Group 1: Partnership Details - The collaboration will involve the establishment of a "Brain Health Center" at Kiang Wu Hospital, providing a one-stop service from early screening to digital cognitive training and follow-up [2]. - The services will cater to all age groups, including individuals aged 60 and above at risk of cognitive impairment and children aged 3 to 18 with neurodevelopmental disorders [2]. - Data security and compliance will be ensured by localizing data storage and adhering to Macau's legal regulations [2]. Group 2: Strategic Significance - The partnership sets a benchmark for the company, facilitating market expansion in the Greater Bay Area by establishing a replicable model for digital therapy in Hong Kong and Macau [3]. - The collaboration will accumulate high-quality real-world data for further scientific research on cognitive function diseases, enhancing the company's technological advantage in providing diagnostic services [3]. - The initiative addresses the urgent health needs in Macau, potentially reducing the incidence of severe dementia and creating sustainable service revenue for the company [3]. - The partnership strengthens the company's academic and research alliances, complementing recent collaborations with national research centers to promote standardized and scalable applications of cognitive digital therapy [3].